Pasithea Therapeutics Updates Conference Presentation Timing

Pasithea Therapeutics Corp has announced a change in the time of its management presentation at the H.C. Wainwright 27th Annual Global Investment Conference to Monday, September 8, at 5:00 PM Eastern Time. CEO Dr. Tiago Reis Marques will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. The presentation will be webcast and can be registered for. The company is currently testing its lead drug candidate, PAS-004, in a Phase 1 clinical trial in advanced cancer patients and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas.

Pasithea Therapeutics Corp. (NASDAQ: KTTA) has announced a change in the time of its management presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation, originally scheduled for September 10, 2025, at 2:30 PM ET, has been rescheduled to Monday, September 8, 2025, at 5:00 PM Eastern Time [1][2].

CEO Dr. Tiago Reis Marques will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event. The presentation will be webcast and can be registered for via the event's website.

Pasithea Therapeutics is a clinical-stage biotechnology company focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565) [1][2].

The conference, taking place September 8-10, 2025, in New York City, provides an opportunity for investors and financial professionals to learn more about the company's progress and future plans. The rescheduling of the presentation allows for more engagement with attendees and potential investors.

References:
[1] https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-shsx7jet6h2l.html
[2] https://www.biospace.com/press-releases/pasithea-therapeutics-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference